Alpha Lipoic Acid
Also sold as: R-Alpha Lipoic Acid, R-ALA
Best-in-class: Thiocid-300
A unique antioxidant that works in both water and fat compartments, regenerates other antioxidants (vitamin C, E, glutathione), and supports glucose metabolism and nerve health.
Alpha Lipoic Acid quick facts
| Suggested dose | 300–600 mg daily (R-form is favored for absorption); take away from metal-containing minerals. |
| How often | daily |
| Who it's for | Blood-sugar, nerve health and antioxidant support. |
The best-evidenced specific use is diabetic peripheral neuropathy, where intravenous and high-dose oral trials show genuine symptom improvement — this is prescription therapy in some countries rather than a wellness supplement. Meta-analyses also show a small consistent weight reduction. The R-isomer is the biologically active one; racemic mixtures contain half inactive S-form. It can lower blood glucose meaningfully, so anyone on insulin or a sulfonylurea needs to account for that.
How Alpha Lipoic Acid actually works
ALA is the cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase — two rate-controlling steps in the TCA cycle — so it sits at the center of mitochondrial fuel handling. It is also unusual among antioxidants in being both water and fat soluble, and it regenerates other antioxidants: it recycles oxidized vitamin C and E and raises intracellular glutathione. Separately it activates AMPK in muscle and improves GLUT4 translocation.
Where to get Alpha Lipoic Acid
Buy Thiocid-300 at Thorne →The evidence for Alpha Lipoic Acid
Graded by what exists behind each claim.
✅ Clinically validated
- RCTs show improved insulin sensitivity and reduced symptoms of diabetic peripheral neuropathy.
- Regenerates the body's other antioxidants (a rare 'universal antioxidant' property).
📊 Correlative data
- Oxidative stress and impaired glucose handling track with metabolic disease and neuropathy.
🧪 Theoretical / extrapolated benefits
- Mitochondrial and longevity roles are mechanistically appealing but less outcome-proven than the glucose/nerve data.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Alpha Lipoic Acid actually does
Lipoic acid's day job is being bolted to an enzyme, and almost nothing in the supplement literature is about that. Lipoamide — lipoic acid amide-linked to a specific lysine — is the swinging arm on the E2 subunit of pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, branched-chain ketoacid dehydrogenase and the glycine cleavage system. The dithiolane ring opens, accepts an acyl group, hands it to coenzyme A, and is re-oxidized by dihydrolipoamide dehydrogenase. The body makes what it needs of this from octanoic acid; it is not a vitamin.
Free lipoic acid is a different molecule from bound lipoamide, and it is a redox drug. Unattached, the reduced form dihydrolipoic acid is a low-potential dithiol that can reduce glutathione disulfide, ascorbyl radical and oxidized coenzyme Q10, which is where the recycling-other-antioxidants claim comes from. It also chelates transition metals. Both properties belong to the unbound pool that a supplement creates and that food does not.
The mechanism most likely to be doing the clinical work is not antioxidant at all. Lipoic acid activates AMP-activated protein kinase in peripheral tissue and inhibits it in the hypothalamus, improves insulin-stimulated glucose uptake through GLUT4 translocation, and activates NRF2 by modifying KEAP1 cysteines. In diabetic nerve the proposed route is improved endoneurial blood flow and reduced oxidative stress rather than a direct analgesic action Beltramo 2021.
The stereochemistry is where the pharmacology and the shelf diverge. Only R-lipoic acid is the natural enantiomer and only it is a substrate for lipoyltransferase; the S-form is a synthetic byproduct. A racemic product delivers half of an active molecule and half of a compound that competes with it for transport and, in cell systems, inhibits some of its effects.
And there is a receptor-level effect nobody markets. Lipoic acid at high concentration inhibits gluconeogenesis and suppresses hypothalamic AMPK, reducing food intake in rodents. That is the mechanistic basis for the weight-loss products and it is a central nervous system action of a compound sold as an antioxidant.
Cell, rodent, human — and where it stops
The chain from enzyme to human works, and the human endpoint is a subjective symptom score in a condition with a large placebo response. That is the surrogate problem on this page.
In cells and animals the effect is on nerve blood flow and redox state. Diabetic rodents show improved nerve conduction and endoneurial perfusion, and the mechanism connects to the same hyperglycemia-driven pathways that the thiamine literature addresses Beltramo 2021.
In people the intravenous evidence came first and it is the strongest. Short courses of intravenous lipoic acid reduced neuropathic symptom scores in diabetic polyneuropathy, and the oral literature that followed has been pooled repeatedly. A meta-analysis and systematic review of oral treatment in diabetic polyneuropathy reports symptom improvement Hsieh 2023, a second systematic review reaches a compatible conclusion Abubaker 2022, and a third pools neuropathic pain across type 1 and type 2 diabetes Orellana-Donoso 2023.
Every one of those endpoints is a rating scale. The Total Symptom Score and the Neuropathy Impairment Score are self-reported or examiner-rated instruments, and painful neuropathy is a condition in which placebo arms routinely improve by 30 percent. The broader analgesic literature has the same shape: a systematic review of lipoic acid across pain disorders finds effects that are real in aggregate and heterogeneous in size Cassanego 2022.
The obstacle to transfer is what has NOT been measured. No adequately powered oral trial has reported nerve conduction velocity, intraepidermal nerve fiber density or corneal nerve morphometry as a primary endpoint over a year. Where a comparable compound was taken to those endpoints in this disease, the symptom improvement did not come with a structural one, which is the pattern this whole file documents.
And the metabolic claims are weaker than the neuropathy ones. Weight loss in trials is on the order of a kilogram or two over months, and glycemic effects are small and inconsistent. The compound's reputation as an insulin sensitizer rests largely on mechanistic work rather than on outcome trials Beltramo 2021.
Alpha Lipoic Acid — which form, and does it matter
R-lipoic acid, racemic lipoic acid and the stabilized sodium salt are three different products and the trials used the racemate. Almost the entire clinical literature, oral and intravenous, used racemic alpha-lipoic acid at 600 mg. An R-only product at 300 mg is not the same intervention and has not been tested at that dose.
Free R-lipoic acid is chemically unstable, which is why the salt exists. The free acid polymerizes on exposure to heat and to gastric acid, forming an insoluble polymer that is not absorbed. Sodium R-lipoate is stabilized against that and gives higher and more reproducible plasma concentrations, which is a genuine formulation advance with no clinical endpoint attached to it.
The exposure numbers explain why dosing is on an empty stomach. Oral bioavailability of racemic lipoic acid is roughly 30 percent, falling substantially when taken with food. Peak plasma concentration arrives in about 30 to 60 minutes and the plasma half-life is very short — on the order of 30 minutes — because first-pass hepatic metabolism is extensive. Degradation runs through beta-oxidation to bisnorlipoate and tetranorlipoate plus S-methylation, and the metabolites undergo renal clearance. There is no meaningful cytochrome step.
That half-life is the awkward fact under every claim on this page. A compound cleared in 30 minutes cannot maintain a steady-state tissue concentration on once-daily dosing, so either the effect is driven by a brief peak, or by a metabolite, or by an induced adaptation such as NRF2 signaling that outlasts the exposure. Nobody has established which, and the trials dosed once daily.
The practical form conclusion. If the goal is to reproduce the neuropathy literature, the product is racemic alpha-lipoic acid at 600 mg taken 30 minutes before a meal. An R-only or stabilized salt product may well be better pharmacokinetically and has no outcome evidence of its own Hsieh 2023.
What would have to be true, and how you would know it was not
1. Predict a symptom score improves and predict you cannot attribute it. On 600 mg daily, predict a measurable improvement in burning, tingling and numbness scores over 4 to 12 weeks in diabetic polyneuropathy Hsieh 2023 Orellana-Donoso 2023, and predict a placebo arm in the same trial improves substantially too Cassanego 2022.
2. Predict the objective nerve measures do not change. Predict no measurable change in nerve conduction velocity or in vibration threshold at 12 weeks. That dissociation is the falsifiable core of this page, and a trial reporting a structural improvement alongside the symptom one would overturn it.
3. The prediction that cuts against the product. Predict essentially no change in HbA1c (hemoglobin A1c) or fasting insulin at 12 weeks on 600 mg, because the glycemic literature is small and inconsistent Beltramo 2021. A properly powered glycemic trial showing a clinically meaningful HbA1c reduction would falsify this.
4. Predict weight change is small enough to be within measurement noise. Predict 1 to 2 kg over 12 to 20 weeks at 1,200 mg a day and predict that a person who cannot detect it on a scale over a month is reading the trial correctly rather than failing to respond.
5. Predict a biotin interaction that nobody checks. Lipoic acid is structurally similar to biotin and competes with it for transport in cell systems. Predict that long-term high-dose use lowers biotin status, and note that no human study has measured it — which makes it a prediction rather than a caution.
What nobody has tested yet
Nobody has run the structural-endpoint trial. Twelve months of 600 mg with intraepidermal nerve fiber density or corneal confocal microscopy as the primary endpoint would settle whether this compound modifies the disease or relieves the symptom Hsieh 2023. It has been possible for a decade.
The R-only question has never been tested clinically. The pharmacology says the racemate is half inactive and the trials all used the racemate Abubaker 2022. A head-to-head at matched R content would either justify the premium or end it.
The half-life paradox is unexplained. A compound cleared in half an hour producing effects on a weeks-long timescale implies a mechanism that outlasts the exposure, and no human study has identified it. Whether it is NRF2-driven transcription, a metabolite, or an incorporation into the bound pool is unresolved.
And the intravenous-to-oral gap has never been reconciled. The intravenous evidence is stronger than the oral evidence at a much higher effective exposure Orellana-Donoso 2023. Whether an oral regimen could reach the same exposure with a stabilized salt and split dosing is a formulation question nobody has asked in a trial.
Alpha Lipoic Acid — its own safety story, not its category's
The common effects are gastrointestinal and dose-related. Nausea, heartburn and abdominal discomfort at 600 mg and above, reduced by taking it well before a meal rather than with one. Skin rash is reported occasionally.
The specific and unusual risk is hypoglycemia, and it matters most in the population that buys this. Lipoic acid improves insulin-stimulated glucose uptake, so added to insulin or a sulfonylurea it is additive. Anyone taking it for diabetic neuropathy is by definition in that group, and glucose monitoring for the first few weeks is the sensible handling Beltramo 2021.
Insulin autoimmune syndrome is rare, real and worth naming. A sulfhydryl-containing compound can trigger insulin autoantibody formation and severe spontaneous hypoglycemia, with a strong HLA association reported predominantly in East Asian populations. It is uncommon and it is the reason unexplained hypoglycemia on this supplement deserves investigation rather than dose adjustment.
Thiamine deficiency is a documented precipitant of harm. Because lipoic acid acts on the same alpha-ketoacid dehydrogenase complexes that need thiamine, giving it to a thiamine-deficient person — chronic alcohol use, bariatric surgery — has been reported to worsen the metabolic picture. Correct thiamine first.
Two more interactions and one exclusion. Lipoic acid chelates metals, so separating it from iron, calcium and magnesium by several hours is reasonable. It has been reported to affect thyroid hormone conversion, which matters on levothyroxine. And there are no safety data in pregnancy or lactation at supplemental doses. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.
Sources read for this page
- Hsieh RY. Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. Nutrients 2023 · PMID 37630823
- Orellana-Donoso M. Effectiveness of alpha-lipoic acid in patients with neuropathic pain associated with type I and type II diabetes mellitus: A systematic review and meta-analysis. Medicine (Baltimore) 2023 · PMID 37933068
- Abubaker SA. Effect of Alpha-Lipoic Acid in the Treatment of Diabetic Neuropathy: A Systematic Review. Cureus 2022 · PMID 35812639
- Cassanego G. Evaluation of the analgesic effect of alpha-lipoic acid in treating pain disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2022 · PMID 35026405
- Beltramo E. Thiamine and diabetes: back to the future?. Acta Diabetol 2021 · PMID 34091762
How you would know if it worked
These are the markers this product's own mechanism names, which makes them the ones that would show it working.
- Vitamin C Retest: 12 weeks after changing intake.
- Fasting Insulin Retest: Every 3–6 months, or 8–12 weeks after an intervention.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Alpha Lipoic Acid — safety & side effects
- Nausea and rash. A distinctive one: it can cause hypoglycemia, and there is a rare insulin autoimmune syndrome associated with it, mostly reported in people carrying a specific HLA type.
- Additive with diabetes medication. It also chelates metals, so separate it from mineral supplements.
- Can lower thyroid hormone levels — monitor if treated. Take it away from food for absorption; biotin depletion is theoretical with long-term use.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Alpha Lipoic Acid in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Alpha Lipoic Acid
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | ALA has real, if modest, glucose-lowering evidence |
| Fasting Insulin | Insulin sensitivity, where the effect shows first |
| Comprehensive Metabolic Panel (CMP) | Fasting glucose — hypoglycemia is possible alongside diabetes medication |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
Alpha Lipoic Acid — frequently asked questions
What is Alpha Lipoic Acid?
A unique antioxidant that works in both water and fat compartments, regenerates other antioxidants (vitamin C, E, glutathione), and supports glucose metabolism and nerve health.
What is the suggested dose of Alpha Lipoic Acid?
300–600 mg daily (R-form is favored for absorption); take away from metal-containing minerals. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Alpha Lipoic Acid dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Alpha Lipoic Acid?
Coach Cam sources Alpha Lipoic Acid from Thorne, with 10% off auto-applied at checkout — use the buy link on this page.
Alpha Lipoic Acid inside a finished plan
One arm of 5 Protocol Blueprints, free to read in full.
What Alpha Lipoic Acid is used for
Alpha Lipoic Acid appears under 6 goals in the goal router.
Related Metabolic & Weight supplements
Where this goes next
Alpha Lipoic Acid is the glycation arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.